So, I am back from JPM Healthcare conference in SanFran. It was a crazy week and a great experience. My 5 takeaways:
(1) It is THE place to be for Pharma / Biotech partnering
(2) Specifically for publicly traded organisations, presenting your company at the conference is a must to enforce your relevancy
(3) The action is outside of the actual conference - majority of people don’t attend the conference but rather meet for business development, investment, or company analysis
(4) Getting invited and attending the right evening receptions is even more critical than formal meetings. I had five receptions in one evening - could only make 3 of the 5 but they were worth it.
(5) And MOST importantly, wear comfortable walking shoes and bring a good umbrella as you are moving between all the various hotels in central SanFran as you race to get to your next meeting.
As mentioned previously, our BenevolentAI's Chairman & acting CEO, Francois Nader presented at the conference and did a fabulous job. He even mentioned my name as the Chief Revenue Officer in spearheading our way forward - quite an honour!
The link to the recording is below. In my PoV it is worth 20 minutes of your time. However, if you don't have time here is my recap:
We are at the intersection of Pharma & Tech and a pioneer & leader in AI-augmented drug discovery, enabled by the Benevolent Platform.
We stand above our competition of AI in drug discovery as not only have we been doing it for 10 years, but we are also one of the rare platforms that has validated our approach via three ways :
(1) Successful collaborations with AstraZeneca with TargetID and most recently Merck Healthcare KGaA with Chemistry. For AstraZeneca the products are in the pipeline and they're real.
(2) We leveraged our indication expansion capabilities to identify Eli Lilly and Company's rheumatoid arthritis drug Olumiant (baricitinib) as a potential treatment for COVID-19, which received an emergency use authorisation from the US FDA in 2020; full approval in May 2022.
(3) Our platform has generated 5 wholly owned products in a pipeline that looks like a traditional Biotech. Our lead asset BEN-8744 is an oral PDE10 inhibitor in Phase I which is a potential first-in-class option for ulcerative colitis.
Our Business model offers multiple routes for value creation. In addition to our high potential R&D pipeline and our leading E2E Drug Discovery solutions mentioned above, we have a new expansion opportunity through suite of Knowledge Exploration tools that acting as a co-pilot for scientists, leverages bio-specific natural language processing (NLP) and large language models (LLM) to surface data, perform analysis, and give scientific recommendations to drive new insights and increase productivity.
So, as you can see from above, this is a very exciting time for BenevolentAI and I am thrilled to be part of the journey!
#JPM2024 #drugdiscovery #aidrugdiscovery #generativeai #researchanddevelopment
Recording available of BenevolentAI’s presentation at the 42nd Annual J.P.Morgan Healthcare Conference
📢 Our Chair and Acting CEO Francois Nader, MD, MBA presented at JPM 2024 last week - you can now watch the presentation on our website, visit the link below 👇
https://lnkd.in/eKNf2KZv
Want to find out more? Get in touch - send an email to investors@benevolent.ai or bd@benevolent.ai.
Financial Marketing ( V.P. ) at Pru-Bache
4moSave the date!